BCSC-1 Polyclonal Antibody
- 货号：YT0483
- 应用：WB;ELISA
- 种属：Human;Rat;Mouse;
- 蛋白名称：
- von Willebrand factor A domain-containing protein 5A
- 免疫原：
- The antiserum was produced against synthesized peptide derived from human LHR2A. AA range:371-420
- 特异性：
- BCSC-1 Polyclonal Antibody detects endogenous levels of BCSC-1 protein.
- 组成：
- Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
- 来源：
- Polyclonal, Rabbit,IgG
- 稀释：
- WB 1:500 - 1:2000. ELISA: 1:20000. Not yet tested in other applications.
- 纯化工艺：
- The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
- 储存：
- -15°C to -25°C/1 year(Do not lower than -25°C)
- 其他名称：
- VWA5A;BCSC1;LOH11CR2A;von Willebrand factor A domain-containing protein 5A;Breast cancer suppressor candidate 1;BCSC-1;Loss of heterozygosity 11 chromosomal region 2 gene A protein
- 背景：
- VWA5A (von Willebrand factor A domain containing 5A), also known as BCSC-1 (breast cancer suppressor candidate 1) or LOH11CR2A (loss of heterozygosity 11 chromosomal region 2 gene A protein), is a 786 amino acid protein containing one VIT domain and one VWFA domain. VWA5A is expressed at low levels in various tissues, with no expression found in 80% of tumor cell lines. Likely acting as a tumor suppressor gene, deletion of VWA5A leads to loss of heterozygosity (LOH) in breast and ovarian tumors, and may have an important role as a potential gene therapy target. Abnormal expression of VWA5A may lead to an increase in adhesion of CNE-2L2 cells associated with an increase in expression of E-cadherin, alpha-catenin, and p53, resulting in a decrease of malignant activity in cells with ectopic expression of VWA5A. Existing as four alternatively spliced isoforms, the gene encoding VWA5A maps to human chromosome 11q24.2.
- 细胞定位：
- nucleus,nucleoplasm,
- 组织表达：
- Expressed at low level in many tissues. Not expressed in 80% of tumor cell lines tested.
- Western Blot analysis of various cells using BCSC-1 Polyclonal Antibody
- Western blot analysis of lysates from 293 cells, using LHR2A Antibody. The lane on the right is blocked with the synthesized peptide.
